Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 7: 839 - 845

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.07.001

Basic research

Emergence of ciprofloxacin heteroresistance in clinical Pseudomonas aeruginosa

  • Congcong LI ,
  • Yufeng YAO ,
  • Chuanzhen ZHANG
Expand
  • Department of Immunology and Microbiology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China
ZHANG Chuanzhen，E-mail: 1049119959@qq.com.

Received date: 2022-04-02

  Accepted date: 2022-05-22

  Online published: 2022-09-04

Supported by

National Natural Science Foundation of China(81830068);National Natural Sciences Fund Youth Fund Project(82102407)

Fold

Abstract

Objective

·To investigate ciprofloxacin heteroresistance in Pseudomonas aeruginosa (PA).

Methods

·Ciprofloxacin heteroresistance in 227 clinical PA strains was initially identified by disk diffusion. Meanwhile, susceptibilities of these strains was classified according to the diameter of the inhibition zone. The stability of the identified heteroresistant strains was tested by measuring the sensitivity after serial passage under antibiotic-free conditions. Mechanisms mediating heteroresistance were analyzed by whole-genome sequencing. Susceptibilities of resistant subpopulations to different antibiotics were also detected.

Results

·Based on disk diffusion, 142 (62.6%), 26 (11.5%), and 59 (26.0%) of 227 isolates were classified as susceptible, intermediate and resistant to ciprofloxacin respectively. Eighteen putative heteroresistant strains were detected through primary disk diffusion selection, and 11 among them were further verified as stable heteroresistant strains by population analysis profiling (PAP). By whole-genome sequencing, 8 and 2 among 11 resistant subpopulations carried mutations in mexS and mutations in gyrA individually. In addition, mutations in fleQ, PA2632 or PAKAF_02255 were detected respectively. Both mexS and gyrA mutants led to moxifloxacin resistance, and some mexS mutants also showed resistance to chloramphenicol and imipenem.

Conclusion

·Ciprofloxacin heteroresistance rate inPA is 4.8% (11/227). As a screening method for heteroresistance of PA, the disk diffusion has low sensitivity and has a certain false negative rate. The mutation mexS is the predominant mutation type in resistant subpopulations and it might enhance the overexpression of efflux pump MexEF-OprN, thus mediating resistance to different antibiotics including ciprofloxacin.

Key words： Pseudomonas aeruginosa; ciprofloxacin; heteroresistance; disk diffusion; population analysis profiling (PAP)

Cite this article

Congcong LI , Yufeng YAO , Chuanzhen ZHANG . Emergence of ciprofloxacin heteroresistance in clinical Pseudomonas aeruginosa[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(7) : 839 -845 . DOI: 10.3969/j.issn.1674-8115.2022.07.001

References

1 GAYNES R, EDWARDS J R, SYSTEM N N I S. Overview of nosocomial infections caused by gram-negative bacilli[J]. Clin Infect Dis, 2005, 41(6): 848-854.
2 KALIL A C, METERSKY M L, KLOMPAS M, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society[J]. Clin Infect Dis, 2016, 63(5): 575-582.
3 LYCZAK J B, CANNON C L, PIER G B. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist[J]. Microbes Infect, 2000, 2(9): 1051-1060.
4 HOOPER D C. New uses for new and old quinolones and the challenge of resistance[J]. Clin Infect Dis, 2000, 30(2): 243-254.
5 ANDRIOLE V T. The quinolones: past, present, and future[J]. Clin Infect Dis, 2005, 41(Suppl 2): S113-S119.
6 LEE J K, LEE Y S, PARK Y K, et al. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase Ⅳ in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa[J]. Int J Antimicrob Agents, 2005, 25(4): 290-295.
7 LLANES C, K?HLER T, PATRY I, et al. Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin[J]. Antimicrob Agents Chemother, 2011, 55(12): 5676-5684.
8 EL-HALFAWY O M, VALVANO M A. Antimicrobial heteroresistance: an emerging field in need of clarity[J]. Clin Microbiol Rev, 2015, 28(1): 191-207.
9 MORAND B, MüHLEMANN K. Heteroresistance to penicillin in Streptococcus pneumoniae[J]. Proc Natl Acad Sci USA, 2007, 104(35): 14098-14103.
10 OKADO J B, AVACA-CRUSCA J S, OLIVEIRA A L, et al. Daptomycin and vancomycin heteroresistance revealed among CC5-SCCmecII MRSA clone and in vitro evaluation of treatment alternatives[J]. J Glob Antimicrob Resist, 2018, 14: 209-216.
11 ANDERSSON D I, NICOLOFF H, HJORT K. Mechanisms and clinical relevance of bacterial heteroresistance[J]. Nat Rev Microbiol, 2019, 17(8): 479-496.
12 JIA X J, MA W J, HE J C, et al. Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia[J]. Int J Antimicrob Agents, 2020, 55(3): 105832.
13 HE J C, JIA X J, YANG S S, et al. Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections[J]. Int J Antimicrob Agents, 2018, 51(3): 413-421.
14 POURNARAS S, IKONOMIDIS A, MARKOGIANNAKIS A, et al. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems[J]. J Med Microbiol, 2007, 56(Pt 1): 66-70.
15 HERMES D M, PORMANN PITT C, LUTZ L, et al. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and-resistant Pseudomonas aeruginosa[J]. J Med Microbiol, 2013, 62(8): 1184-1189.
16 MEI S C, GAO Y L, ZHU C T, et al. Research of the heteroresistance of Pseudomonas aeruginosa to imipenem[J]. Int J Clin Exp Med, 2015, 8(4): 6129-6132.
17 NICOLOFF H, HJORT K, LEVIN B R, et al. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification[J]. Nat Microbiol, 2019, 4(3): 504-514.
18 XU Y, ZHENG X K, ZENG W L, et al. Mechanisms of heteroresistance and resistance to imipenem in Pseudomonas aeruginosa[J]. Infect Drug Resist, 2020, 13: 1419-1428.
19 OH H, STENHOFF J, JALAL S, et al. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains[J]. Microb Drug Resist, 2003, 9(4): 323-328.
20 GOLI H R, NAHAEI M R, REZAEE M A, et al. Contribution of mexAB-oprM and mexXY (-oprA) efflux operons in antibiotic resistance of clinical Pseudomonas aeruginosa isolates in Tabriz, Iran[J]. Infect Genet Evol, 2016, 45: 75-82.
21 J?RGENSEN K M, WASSERMANN T, JENSEN P ?, et al. Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2013, 57(9): 4215-4221.
Options
Outlines

/

〈 〉